Niels Gregersen

Niels Gregersen

Auto-generated profile, based on publicly available information

Niels Gregersen

Research Unit for Molecular Medicine, Department of Clinical Medicine, Aarhus University and Aarhus University Hospital, 8200 Aarhus, Denmark

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
SMSigne Mosegaard
Signe Mosegaard
GDGraziana Dipace
Graziana Dipace
Peter BrossPeter Bross
Peter Bross
JCJasper Carlsen
Jasper Carlsen
NGNiels Gregersen
Niels Gregersen
RORikke Katrine Jentoft Olsen
Rikke Katrine Jentoft Olsen
As an essential vitamin, the role of riboflavin in human diet and health is increasingly being highlighted. Insufficient dietary intake of riboflavin is often reported in nutritional surveys and population studies, even in non-developing countries with abundant sources of riboflavin-rich dietary products. A latent subclinical riboflavin deficiency can result in a significant clinical phenotype when combined with inborn genetic disturbances or environmental and physiological factors like infections, exercise, diet, aging and pregnancy. Riboflavin, and more importantly its derivatives, flavin mononucleotide (FMN) and flavin adenine dinucleotide (FAD), play a crucial role in essential cellular processes including mitochondrial energy metabolism, stress responses, vitamin and cofactor biogenesis, where they function as cofactors to ensure the catalytic activity and folding/stability of flavoenzymes. Numerous inborn errors of flavin metabolism and flavoenzyme function have been described, and supplementation with riboflavin has in many cases been shown to be lifesaving or to mitigate symptoms. This review discusses the environmental, physiological and genetic factors that affect cellular riboflavin status. We describe the crucial role of riboflavin for general human health, and the clear benefits of riboflavin treatment in patients with inborn errors of metabolism.

29 June 2021 in Biomolecules
Verified
Journal Article
Open access
PDF file
PFPaula Fernandez-Guerra
Paula Fernandez-Guerra
AGAna C. Gonzalez-Ebsen
Ana C. Gonzalez-Ebsen
SBSusanne Eriksen Boonen
Susanne Eriksen Boonen
JCJulie Courraud
Julie Courraud
NGNiels Gregersen
Niels Gregersen
LBLouise Schouborg Brinth
Louise Schouborg Brinth
Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a heterogeneous, debilitating, and complex disease. Along with disabling fatigue, ME/CFS presents an array of other core symptoms, including autonomic nervous system (ANS) dysfunction, sustained inflammation, altered energy metabolism, and mitochondrial dysfunction. Here, we evaluated patients’ symptomatology and the mitochondrial metabolic parameters in peripheral blood mononuclear cells (PBMCs) and plasma from a clinically well-characterised cohort of six ME/CFS patients compared to age- and gender-matched controls. We performed a comprehensive cellular assessment using bioenergetics (extracellular flux analysis) and protein profiles (quantitative mass spectrometry-based proteomics) together with self-reported symptom measures of fatigue, ANS dysfunction, and overall physical and mental well-being. This ME/CFS cohort presented with severe fatigue, which correlated with the severity of ANS dysfunction and overall physical well-being. PBMCs from ME/CFS patients showed significantly lower mitochondrial coupling efficiency. They exhibited proteome alterations, including altered mitochondrial metabolism, centred on pyruvate dehydrogenase and coenzyme A metabolism, leading to a decreased capacity to provide adequate intracellular ATP levels. Overall, these results indicate that PBMCs from ME/CFS patients have a decreased ability to fulfill their cellular energy demands.

Verified
Journal Article
Open access
PDF file
ALAllan M Lund
Allan M Lund
FWFlemming Wibrand
Flemming Wibrand
KSKristin Skogstrand
Kristin Skogstrand
Marie Bækvad-HansenMarie Bækvad-Hansen
Marie Bækvad-Hansen
NGNiels Gregersen
Niels Gregersen
RORikke Katrine Jentoft Olsen
Rikke Katrine Jentoft Olsen
Historically, the analyses used for newborn screening (NBS) were biochemical, but increasingly, molecular genetic analyses are being introduced in the workflow. We describe the application of molecular genetic analyses in the Danish NBS programme and show that second-tier molecular genetic testing is useful to reduce the false positive rate while simultaneously providing information about the precise molecular genetic variant and thus informing therapeutic strategy and easing providing information to parents. When molecular genetic analyses are applied as second-tier testing, valuable functional data from biochemical methods are available and in our view, such targeted NGS technology should be implemented when possible in the NBS workflow. First-tier NGS technology may be a promising future possibility for disorders without a reliable biomarker and as a general approach to increase the adaptability of NBS for a broader range of genetic diseases, which is important in the current landscape of quickly evolving new therapeutic possibilities. However, studies on feasibility, sensitivity, and specificity are needed as well as more insight into what views the general population has towards using genetic analyses in NBS. This may be sensitive to some and could have potentially negative consequences for the NBS programme.

28 March 2018 in European Journal of Pediatrics
Verified
Journal Article
Closed access
PDF file
SJShivani Joshi
Shivani Joshi
HKHelene Kvistgaard
Helene Kvistgaard
KKKonstantinos Kamperis
Konstantinos Kamperis
MFMia Færch
Mia Færch
SHSøren Hagstrøm
Søren Hagstrøm
JCJane Hvarregaard Christensen
Jane Hvarregaard Christensen